Examples of using Immediate-release exenatide in English and their translations into Polish
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Clinical studies with immediate-release exenatide have indicated improved beta-cell function, using measures such as the homeostasis model assessment for beta-cell function(HOMA-B) and the proinsulin to insulin ratio.
more than 4 hours after immediate-release exenatide injection.
Immediate-release exenatide can be administered at any time within the 60-minute period before the morning
Immediate-release exenatide lowered HbA1c by 1.1% from a baseline of 8.3%
body weight in patients treated for 30 weeks in three placebo-controlled studies, whether the immediate-release exenatide was added to metformin,
one of 26 weeks duration, with 121 and 111 immediate-release exenatide and 112 and 54 placebo treated patients respectively, added to existing thiazolidinedione treatment, with or without metformin.
based on conventional studies of safety pharmacology, repeat-dose toxicity, or genotoxicity conducted with immediate-release exenatide or prolonged-release exenatide. .
after meals and at 3 am) demonstrated significantly reduced glucose values compared to insulin in the postprandial periods after immediate-release exenatide injection.
insulin glargine was added to existing therapy of immediate-release exenatide and metformin, metformin
In insulin-comparator studies immediate-release exenatide(5 mcg BID for 4 weeks,
Immediate-release exenatide(5 mcg BID for 4 weeks,
There were no episodes of major hypoglycaemia in the immediate-release exenatide arm.
At the end of the study, immediate-release exenatide(n=137) demonstrated a statistically significant reduction in the HbA1c and weight compared to placebo n=122.
Immediate-release exenatide must not be administered by intravenous or intramuscular injection.
Immediate-release exenatide should not be administered after a meal.
Immediate-release exenatide and basal insulin must be administered as two separate injections.
Immediate-release exenatide has shown no adverse effects on lipid parameters.
Rate based on immediate-release exenatide completed long-term efficacy and safety studies n=5763
Immediate-release exenatide is not expected to have any clinically relevant effects on the pharmacokinetics of metformin or sulphonylureas.
About half of this 6%(3% of the total patients given immediate-release exenatide in the controlled studies),